Preventive Effects of <i>Ophiocordyceps </i><i>s</i><i>inensis </i>Mycelium on High-Fat Diet Induced Lipid Dysregulation and Hepatic Inflammation of Mice

Chung‐Hsi Chou, Hui‐Wen Lin, Yi‐Hsieng Samuel Wu, Yi‐Ling Lin, Chia‐Chun Chiang, Shih‐Guei Fu, Yi‐Chen ChenJournal of Food and Nutrition Research 2017 · DOI

TL;DR

This study investigates the potential of Ophiocordyceps sinensis mycelium (OSM) as a dietary supplement to counteract the negative effects of a high-fat diet (HFD) in mice. The findings suggest that OSM can effectively mitigate HFD-induced lipid dysregulation and reduce liver inflammation, offering a promising avenue for managing metabolic disorders.

What Problem Does This Paper Address?

The paper tackles the growing global health concern of metabolic syndromes, such as hyperlipidemia and fatty liver disease, which are strongly linked to modern, westernized lifestyles and imbalanced diets. These conditions are significant risk factors for cardiovascular disease and overall mortality. While the liver plays a crucial role in lipid homeostasis, it is also susceptible to damage from diets high in fat. The researchers aim to explore whether Ophiocordyceps sinensis mycelium, a traditional medicinal ingredient, can offer a protective effect against these diet-induced pathologies.

Methods

The study employed a controlled experimental design using C57BL/6 mice. Sixty mice were divided into five groups: a control group fed a standard chow diet, and four groups fed a high-fat diet (HFD). Three of the HFD groups received varying dosages of OSM (low, medium, and high), while one HFD group received a placebo.

Key methodologies included:

  • Dietary Intervention: Mice were fed either a control diet or an HFD for 20 weeks.
  • OSM Supplementation: Oral administration of OSM was given to the supplemented HFD groups.
  • Biochemical Analysis: Blood and liver samples were analyzed for various biochemical markers, including serum lipids (triglycerides, total cholesterol, HDL-C, LDL-C), liver enzymes (AST, ALT, ALP), and inflammatory cytokines (TNF-α, IL-1β).
  • Histopathological Examination: Liver tissues were examined using Hematoxylin and Eosin (H&E) staining to assess general morphology and inflammation, and Oil Red O staining to visualize lipid accumulation (steatosis).
  • Lipid Profiling: Serum, liver, and fecal lipid levels were quantified.
  • Antioxidant Capacity Assays: Measures of lipid peroxidation (TBARS) and antioxidant enzymes (GSH, TEAC, SOD, CAT, GPx) were performed.
  • Statistical Analysis: Data was analyzed using analysis of variance (ANOVA) with Duncan's multiple range test for post-hoc comparisons.

Datasets

Not discussed in the paper. The study utilized experimental mice as the biological system for data generation.

Key Insights and Ideas

  • OSM as a Lipid Regulator: The most striking finding is OSM's ability to significantly reduce serum triglyceride (TG) and low-density lipoprotein cholesterol (LDLC) levels in mice fed a high-fat diet. This directly addresses the dyslipidemia aspect of metabolic syndrome.
  • Mitigating Hepatic Inflammation: OSM supplementation also showed a protective effect against HFD-induced liver damage, evidenced by reduced levels of liver enzymes (AST, ALT) and the pro-inflammatory cytokine TNF-α.
  • Promoting Cholesterol Excretion: While not directly impacting liver TG, OSM appears to promote the excretion of cholesterol into the feces, contributing to lower overall cholesterol levels.
  • Complex Antioxidant Effects: While OSM did not universally boost all antioxidant markers, it did reduce lipid peroxidation (TBARS) and, in some cases, increased reduced glutathione (GSH) and amended reduced GPx activity, suggesting a nuanced role in oxidative stress management.
  • OSM's Potential Beyond Direct Lipid Lowering: The discussion hints that OSM might modulate energy expenditure and mitochondrial function, contributing to its overall metabolic benefits, rather than solely acting as a lipase inhibitor.

Key Results

  • OSM supplementation significantly decreased serum triglyceride (TG) and total cholesterol (TC) levels in HFD-fed mice (p<0.05).
  • OSM also reduced serum low-density lipoprotein cholesterol (LDLC) levels and the LDLC/HDL-C atherosclerosis index in HFD-fed mice (p<0.05).
  • Liver TG levels were significantly reduced by OSM supplementation (p<0.05).
  • OSM attenuated elevated serum AST and ALT levels, as well as liver TNF-α levels, in HFD-fed mice (p<0.05).
  • Histological analysis confirmed that OSM supplementation reduced lipid accumulation (steatosis) in the liver.
  • Fecal cholesterol levels were significantly increased in the medium-dose OSM group (p<0.05).

Limitations and Future Work

  • Animal Model vs. Human Application: The study was conducted in mice, and direct translation of these findings to human health requires further investigation.
  • Mechanism of Action: While several beneficial effects were observed, the precise molecular mechanisms by which OSM exerts its protective effects are not fully elucidated. The paper suggests potential roles in energy expenditure and mitochondrial function, which warrant further exploration.
  • Long-Term Effects: The study was conducted over 20 weeks. Longer-term studies could provide more comprehensive insights into the sustained effects of OSM.
  • Specific Components: The study used OSM, which contains various bioactive compounds. Future research could focus on identifying and isolating the specific components responsible for the observed effects.
  • Dietary Intake: While OSM supplementation did not significantly alter food or water intake, the paper notes that the HFD group had lower food intake than the control group, which could be a confounding factor.

The authors suggest that OSM's ability to modulate lipid homeostasis through mechanisms like enhanced fecal excretion and potentially increased energy expenditure makes it a promising nutraceutical for managing HFD-induced metabolic disorders.

Summary updated

Abstract

Dyslipidemia is regarded as one of risk factors related to cardiovascular disease and hepatosteatosis widely. Due to westernized diet habits and lifestyle changes, there is a high prevalence of those lipid-dysregulated diseases, i.e. fatty liver, hyperlipidemia, diabetes etc. However, the liver holds the lipid homeostasis so hepatoprotective nutraceuticals against high-fat diet (HFD) induced dyslipidemia may be potential for a public demand. This study demonstrated that OSM containing 10% polysaccharides and 0.25% adenosine can decrease (pOphiocordyceps sinensis mycelium (OSM) also decreased (p<0.05) serum low-density lipoprotein cholesterol (LDLC) levels and the atherosclerosis index (LDLC/high-density lipoprotein cholesterol (HDLC)) in HFD fed mice. Regarding the liver damage, OSM supplementation attenuated serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values, and liver tumor necrosis factor-α (TNF-α) levels in HFD fed mice. Taken together, OSM showed an ameliorative effect of the hepatosteatosis development and lipid-dysregulated-related diseases in a HFD habit.
BibTeX
@article{chou2017preventive,
  author = {Chung‐Hsi Chou and Hui‐Wen Lin and Yi‐Hsieng Samuel Wu and Yi‐Ling Lin and Chia‐Chun Chiang and Shih‐Guei Fu and Yi‐Chen Chen},
  title = {{Preventive Effects of \&lt;i\&gt;Ophiocordyceps \&lt;/i\&gt;\&lt;i\&gt;s\&lt;/i\&gt;\&lt;i\&gt;inensis \&lt;/i\&gt;Mycelium on High-Fat Diet Induced Lipid Dysregulation and Hepatic Inflammation of Mice}},
  journal = {Journal of Food and Nutrition Research},
  year = {2017},
  doi = {10.12691/jfnr-5-11-10},
}
Figure